Martínez Rodrigo, AbelMas Zubiri, AliciaFernández-Cotrina, JavierBelinchón-Lorenzo, SilviaOrden Gutiérrez, José AntonioArias, PabloFuente López, Ricardo De LaCarrión Herrero, Francisco JavierDomínguez Bernal, Gustavo Ramón2024-01-112024-01-112019Molina-Rueda F, Fernández-González P, Cuesta-Gómez A, Koutsou A, Carratalá-Tejada M, Miangolarra JC. Test-Retest Reliability of a Conventional Gait Model for Registering Joint Angles during Initial Contact and Toe-Off in Healthy Subjects. Int J Environ Res Public Health. 2021 Feb 15;3(18):1343-520147-957110.1016/j.cimid.2019.05.009https://hdl.handle.net/20.500.14352/92568HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, respectively, compared to those obtained in the control group of dogs. The observed security and potential to fight ex vivo L. infantum infection highlight a HisAK70 heterologous immunization strategy as a promising alternative to evaluate its effectiveness against canine VL.engAttribution-NonCommercial-NoDerivatives 4.0 Internationaljournal articlehttps://doi.org/10.1016/j.cimid.2019.05.009https://www.sciencedirect.com/science/article/pii/S0147957119300888?restricted access636.09:615.37Zoonotic infectionVisceral leishmaniosisDogsVaccinationHisAK70DendriticcellsCanineleishmaniosisCiencias Biomédicas32 Ciencias Médicas